Contravisory Investment Management Inc. boosted its holdings in Hologic, Inc. (NASDAQ:HOLX – Free Report) by 267.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,293 shares of the medical equipment provider’s stock after purchasing an additional 5,307 shares during the period. Contravisory Investment Management Inc.’s holdings in Hologic were worth $591,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. GPS Wealth Strategies Group LLC bought a new position in Hologic during the 1st quarter worth approximately $28,000. Sageworth Trust Co bought a new stake in shares of Hologic in the 1st quarter worth approximately $34,000. Salem Investment Counselors Inc. lifted its holdings in shares of Hologic by 163.9% in the 2nd quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 341 shares during the last quarter. Clear Street Markets LLC lifted its holdings in shares of Hologic by 91.3% in the 1st quarter. Clear Street Markets LLC now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 231 shares during the last quarter. Finally, Whittier Trust Co. lifted its holdings in shares of Hologic by 55.5% in the 1st quarter. Whittier Trust Co. now owns 591 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 211 shares during the last quarter. Institutional investors own 92.64% of the company’s stock.
Hologic Trading Up 0.9 %
Shares of Hologic stock traded up $0.62 on Monday, hitting $72.43. 664,209 shares of the company’s stock traded hands, compared to its average volume of 1,595,887. The firm’s 50-day moving average price is $76.35 and its two-hundred day moving average price is $79.30. The stock has a market capitalization of $17.74 billion, a PE ratio of 37.20 and a beta of 1.01. Hologic, Inc. has a one year low of $59.78 and a one year high of $87.88. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.42 and a quick ratio of 3.73.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $95.00 price target on shares of Hologic in a report on Tuesday, August 1st. Bank of America cut their price target on Hologic from $94.00 to $86.00 and set a “neutral” rating on the stock in a report on Tuesday, August 1st. TheStreet cut Hologic from a “b” rating to a “c+” rating in a research report on Monday, July 31st. Raymond James lowered their target price on Hologic from $100.00 to $95.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 1st. Finally, StockNews.com initiated coverage on Hologic in a research report on Friday, August 18th. They issued a “buy” rating on the stock. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $88.92.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
- Five stocks we like better than Hologic
- Canada Bond Market Holiday: How to Invest and Trade
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Trading Halts Explained
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.